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HR  ! 72 beats/min in response to SHOT was associated with 
a better prognosis in patients with PH due to chronic throm-
boembolism to the lung and PH from chronic lung disease. 
 Conclusions:  SHOT leads to characteristic hemodynamic re-
sponses across different forms of PH. The preserved capabil-
ity to acutely respond to SHOT with HR reduction is of prog-
nostic significance in patients with non PAH PH. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Pulmonary hypertension (PH) develops in a variety of 
diseases and leads to functional impairment and a poor 
prognosis. Right heart catheterization (RHC) is warrant-
ed in every patient with suspect PH to facilitate therapeu-
tic decision making  [1] . Although invasive, RHC is a safe 
procedure in experienced hands  [2] and is the gold stan-
dard to evaluate complete pulmonary hemodynamics. 
RHC is mandatory to establish the diagnosis of PH (i.e. 
mean pulmonary artery pressure, PAP,  6 25 mm Hg), 
differentiate between pre- and postcapillary forms (pul-
monary capillary wedge pressure, PCWP,  ^  15 or  1 15 
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 Abstract 
 Background: Pulmonary hypertension (PH) of various 
causes leads to a poor prognosis. Pulmonary vasoreactivity 
testing during right heart catheterization (RHC) has prog-
nostic and therapeutic consequences.  Objective: To charac-
terize the acute hemodynamic response to short-term oxy-
gen supplementation (SHOT) in adult PH patients and its im-
pact on prognosis.  Methods: After a stable baseline period, 
104 patients with PH [pulmonary arterial hypertension (PAH; 
n = 56), chronic thromboembolic (PH; n = 22) or respirato - 
ry diseases (PH; n = 26)], who were mainly therapy-naïve 
(86.5%) (mean p O 2 64.5  8 1.2 mm Hg), received a standard-
ized SHOT during RHC and hemodynamic response was as-
sessed for its prognostic potential.  Results: SHOT signifi-
cantly reduced heart rate (HR: 78.9  8 1.5 to 74  8 1.5 beats/
min), cardiac output (4  8 0.1 to 3.8  8 0.1 l/min), pulmonary 
arterial pressure (46.4  8 1.3 to 42.3  8 1.3 mm Hg) and pul-
monary vascular resistance (10.1  8 0.5 to 9.6  8 0.5 Wood 
units; all p  ! 0.001) compared to baseline. The magnitude of 
this effect varied between the different PH groups. During a 
median follow-up of 25.1 months (range: 0.2–73.3 months), 
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mm Hg) and to determine parameters of prognostic val-
ue  [1] . Pulmonary arterial hypertension (PAH), PH due 
to chronic thromboembolism to the lung (CTEPH) or PH 
in the context of chronic lung disease with or without hy-
poxemia represent the majority of precapillary PH pa-
tients  [3] . In order to identify a small subgroup of PAH 
patients with preserved pulmonary vasoreactivity with 
excellent prognosis who might benefit from high-dose 
calcium channel blockers  [1] , a vasoreactivity test with 
short-acting pulmonary vasodilators is recommended 
during RHC. In adults, vasoreactivity testing is usually 
done using intravenous epoprostenol or inhalatory ap-
proaches with inhaled nitric oxide or iloprost aerosol  [4–
6] . While vasoreactivity testing with inhaled oxygen is 
well established in pediatric PH patients  [7–9] , this ap-
proach has never been investigated systematically in an 
adult PH patient population.
 We aimed to describe acute hemodynamic effects fol-
lowing a short-term application of oxygen (SHOT) dur-
ing RHC in a group of patients with precapillary PH of 
different etiologies and to detect prognostic implications 
of SHOT-induced possible response patterns.
 Methods 
 This study comprised 104 consecutive patients with suspected 
or established and clinically stable precapillary PH who were 
scheduled for RHC for clinical reasons. CTEPH patients with 
proximal disease who were assessed as operable in terms of pul-
monary endarterectomy were excluded from the analysis.
 Informed consent was obtained from all patients; the study 
was conducted in accordance with the principles of the Declara-
tion of Helsinki and was approved by the institutional ethics com-
mittee.
 Treatments at study entry varied. Twenty-three (n = 23) pa-
tients were already on domiciliary oxygen therapy. Most patients 
were naïve for specific PAH medications (n = 90). Otherwise, PAH 
patients included were treated with inhaled iloprost (n = 8), bosen-
tan (n = 4), sildenafil (n = 1) and high-dose calcium channel block-
ers (n = 1). Except for oxygen therapy, all medications were dis-
continued 12 h before RHC. Oxygen therapy was paused at least 
2 h before RHC. Since we did not perform a prospective therapeu-
tic study with predefined treatment regimens, we were not able to 
evaluate different therapeutic effects.
 RHC and Hemodynamic Testing 
 RHC was performed as reported previously  [10] . Briefly, a 
Swan-Ganz catheter (Criti-Cath; Becton-Dickinson; Temse, Bel-
gium) and an arterial line were inserted into the femoral vein and 
artery, respectively. All measurements were performed in recum-
bent position. Hemodynamic parameters included systemic arte-
rial (SAP) and right atrial pressure (RAP), PAP and PCWP. Car-
diac output (CO) was assessed using the thermodilution method 
(Cardiac Output Computer; Edwards Laboratories; Santa Ana, 
Calif., USA). Arterial blood gases and mixed venous oxygen gen-
eration (S v O 2 ) were measured. Pulmonary (PVR) and systemic 
vascular resistance (SVR) were calculated using standard formu-
las.
 All measurements were taken at a stable baseline period with-
out oxygen of at least 2 h (baseline). Standardized oxygen was 
given via standard commercial equipment at a flow rate of 5 l/min 
to achieve an oxygen saturation of at least 90% in every patient. 
Oxygen was applied for at least 10 min. Hemodynamic parame-
ters were again recorded when stable parameters for oxygen satu-
ration, heart rate (HR), breathing frequency and PAP and SAP 
had been noted.
 Survival Estimates 
 The observation period started with the day of RHC and end-
ed when the patient died or received transplantation. A total num-
ber of 8 patients received lung transplantation and were included 
as ‘alive’ until the day of transplantation and censored thereafter. 
All non-survivors died of cardiorespiratory failure. No patient 
was lost to follow up.
 Statistical Analysis 
 Values are presented as means, medians, SEM and/or ranges, 
respectively. Comparisons were made based on the normal distri-
bution of parameters using Student’s t test or the non-parametric 
Mann-Whitney test. The effect of oxygen on hemodynamic pa-
rameters and blood gases was calculated in a paired fashion of the 
t test. One-factorial ANOVA with Bonferroni correction for mul-
tiple testing was performed when more than two groups were 
compared. The percentage of surviving patients at each time point 
was estimated with the Kaplan-Meier method.
 A value of p  ! 0.05 was considered statistically significant. The 
statistical software used was SPSS 15.0 for Windows  .
 Results 
 Patient Characteristics 
 Patient characteristics are listed in  table  1 . Arterial 
 oxygen saturation (S a O 2 ) was higher in PAH patients 
than in those with PH from chronic lung disease or 
CTEPH. All other parameters were not significantly dif-
ferent.
 Hemodynamic Response to Supplemental Oxygen 
 Overall, SHOT did not cause any adverse events, but 
significantly increased oxygen partial pressure (p O 2 ; 
  p O 2 +54.8  8 3.9 mm Hg), S a O 2 (  S a O 2 +8.8  8 0.7%) and 
S v O 2 (  S v O 2 +8.8  8 0.8 %), as expected (all p  ! 0.001; 
table 2 ). In response, HR (  HR –4.9  8 0.7 beats/min), 
CO (  CO –252  8 30 ml) and mean PAP (  PAP –4  8 0.4 
mm Hg), as well as PVR (  PVR –0.5  8 0.1 Wood units, 
WU) decreased (all p  ! 0.001;  fig.  1 ). While SAP and 
PCWP were mainly unchanged, RAP was reduced (  RAP 
–0.3  8 0.1 mm Hg; p  ! 0.05) and SVR increased (  SVR 
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+1.6  8 0.3 WU; p  ! 0.001). All these effects disappeared 
15 min after discontinuation of oxygen supplementation 
(data not shown).
 In the PAH group, improved oxygenation (  p O 2 +61 
 8 5.5 mm Hg,   S a O 2 +7.4  8 0.9%,   S v O 2 +8.1  8 1.1%; 
all p  ! 0.001) was paralleled by reductions in HR (  HR 
–3.5  8 0.9 beats/min), CO (  CO –221  8 37 ml) and 
mean PAP (  PAP –3.3  8 0.5 mm Hg; all p  ! 0.001). PVR 
was not significantly affected.
 In the patients with PH from chronic lung disease and 
CTEPH, SHOT improved p O 2 (  p O 2 +45  8 4.6 mm Hg), 
as well as S a O 2 (  S a O 2 +10.3  8 1.2 %) and S v O 2 (  S v O 2 +9.7 
 8 1.1 %; all p  ! 0.001). In response, HR (  HR –6.5  8 
1 beats/min), CO (  CO –290  8 49 ml) and mean PAP 
(  PAP –4.9  8 0.6 mm Hg) dropped (all p  ! 0.001). A 
mild reduction in PVR (  PVR –0.7  8 0.2 WU) was also 
observed (p = 0.001).
 Reductions in HR and mean PAP were more promi-
nent in the PH patients than in the PAH group (all p  ! 
0.05), while p O 2 increase was pronounced in the PAH 
group (p  ! 0.05).
 Further subdivision of the PH group revealed that all 
parameters changed equally in these two subgroups (data 
not shown).
 Influence of Baseline Hypoxemia on the Acute 
Hemodynamic Response to Oxygen 
 Oxygenation improved in all patients, as expected. 
Neither the reduction in mean PAP nor that of CO was 
related to the baseline p O 2 . However, a significant reduc-
tion in HR was already observed in patients with mild 
baseline hypoxemia (p O 2  ! 65 mm Hg).
Table 1.  Characteristics of the study cohort and subgroups
All patients
(n = 104)
PAH
(n = 56)
non PAH PH 
(n = 48)
Gender (F/M) 57/47 40/16 17/31
Age, years 55.481.5 54.682.3 56.582
Venice class I 56 56 –
iPAH 38 38 –
Scleroderma 11 11 –
PDA 2 2 –
PCH 2 2 –
ASD 1 1 –
VSD 1 1 –
Portopulmonary Hyp. 1 1 –
Venice class III 26 – 26
IPF 10 – 10
Unspecific PF 9 – 9
Post-TBC 3 – 3
COPD 2 – 2
CF 2 – 2
Venice class IV 22 – 22
Non-operable CTEPH 22 – 22
HR, beats/min 78.881.4 76 .881.8 81.182.1
CO, l/min 480.1 480.1 480.1
Mean PAP, mm Hg 46.481.3 4781.8 45.581.8
PVR, WU 10.180.5 10.280.6 1080.7
Mean SAP, mm Hg 95.781.5 95.582.0 96.182.3
PCWP, mm Hg 8.980.4 9.180.5 8.680.5
SvO2, % 56.581.0 57.681.2 55.281.6
FVC, liter 2.980.1 2.980.2 2.980.2
FVC, % 82.882.6 88.183.3 76.783.9
TLC, liter 5.180.2 580.2 5.280.2
TLC, % 88.382 92.182.5 83.883.1
FEV1, liter 2.380.1 2.280.1 2.380.1
FEV1, % 78.782.6 82.883.2 74.684.2
TLCO, % 54.082.6 56.382.9 51.284.5
FEV1/FVC, % 78.3581.0 78.1781.2 78.5681.6
pO2, mm Hg 64.581.7 66.582.2 61.582.4
SaO2, % 87.580.8 89.481.0 85.381.3*
pCO2, mm Hg 37.580.8 37.681.1 37.3.81.2
Hb, mg/dl 14.780.2 14.680.3 14.980.3
Mea ns 8 SEM. PAH includes idiopathic PAH (iPAH; n = 38); 
scleroderma-associated PAH (n = 11), corrected patent ductus ar-
teriosus (PDA; n = 2); corrected atrial septal defect (ASD; n = 1); 
corrected ventricular septum defect (VSD; n = 1); portopulmo-
nary hypertension (n = 1), and pulmonary capillary hemangio-
matosis (PCH; n = 2). PH without PAH includes CTEPH (n = 22) 
and PH from chronic lung disease (n = 26). CF = Cystic fibrosis; 
COPD = chronic obstructive pulmonary disease; FEV1 = forced 
expiratory volume in 1 s; FVC = forced vital capacity; Hb = hemo-
globin; IPF = idiopathic pulmonary fibrosis; pC O 2 = carbon diox-
ide partial pressure; PCH = pulmonary capillary hemangiomato-
sis; PF = pulmonary fibrosis; TBC = tuberculosis; TLC = total lung 
capacity; TLCO = transfer factor of the lung for carbon monoxide; 
* p < 0.05.
Table 2.  Acute hemodynamic changes during oxygen supplemen-
tation (whole study population; means 8 SEM)
Baseline Oxygen p value
Mean SAP, mm Hg 95.481.4 94.781.5 NS
SVR, WU 2380.7 24.780.8 <0.001
RAP, mm Hg 7.180.4 6.880.4 0.01
CO, l/min 480.1 3.880.1 <0.001
HR, beats/min 78.981.5 7481.5 <0.001
Mean PAP, mm Hg 46.481.3 42.381.3 <0.001
PVR, WU 10.180.5 9.680.5 <0.001
pO2, mm Hg 63.981.6 118.784.8 <0.001
SvO2, % 55.881.0 64.580.9 <0.001
SaO2, % 87.580.8 96.280.5 <0.001
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 Characteristics of Survivors and Non-Survivors  
 Overall, during a mean follow-up of 27.7  8 6 months 
(median 25.1; range 0.2–73.3), 32 patients died (31%). 
Those patients had higher brain natriuretic peptide 
(BNP) levels, higher HR during oxygen treatment and a 
lower S a O 2 (each p  ! 0.05) and S v O 2 (p  ! 0.01) at baseline 
( table 3 )
 There was no significant difference in the studied pa-
rameters between survivors and non-survivors (n = 12) 
in the PAH subgroup.
 In patients with PH from chronic lung disease or 
CTEPH, non-survivors (n = 20; 41.7%) had a higher BNP 
level and HR during oxygen supplementation (p  ! 0.05), 
while baseline p O 2 and S v O 2 were lower in the patients 
who died (p  ! 0.05). In addition, the surviving patients 
had a better PVR response to SHOT (p  ! 0.05).
 Risk Estimates of Mortality 
 In univariate analysis of the whole study population 
( table 4 ), BNP  1 180 pg/ml, S a O 2  ! 88% and S v O 2  ! 58% at 
baseline were predictors of mortality. During SHOT, HR 
 1 72 beats/min was the only parameter that predicted 
mortality. During multivariate analysis BNP  1 180 pg/ml 
(hazard ratio 2.2; range 1.1–4.5; p  ! 0.05) and HR  1 72 
beats/min during oxygen application (hazard ratio 2.1; 
range 1–4.6; p  ! 0.05) remained predictors of death. 
 In the PAH group, univariate analysis revealed that 
S v O 2  ! 56% (hazard ratio 3.3; range 1–11; p  ! 0.05) at base-
line was associated with mortality.
 In PH from chronic lung diseases or CTEPH, univar-
iate analysis showed that a BNP level  1 160 pg/ml (hazard 
ratio 3.4; range 1.4–8.4; p  ! 0.01), baseline values of p O 2 
 ! 65 mm Hg (hazard ratio 3.2; range 1.3–7.8; p  ! 0.05), 
Table 3.  Characteristics of survivors and non-survivors (means 8 SEM)
Survivors Non-
survivors
p value
Age, years 54.381.9 57.782.7 NS
BNP, pg/ml 165.7825.8 302.1876.5 <0.05
Baseline CO, l/min 4.180.1 3.880.2 NS
CO during SHOT, l/min 3.980.1 3.580.2 NS
Baseline HR, beats/min 77.281.7 82.482.5 NS
HR during SHOT, beats/min 72.281.8 78.782.5 <0.05
Mean baseline PAP, mm Hg 46.781.6 45.782.2 NS
Mean PAP during SHOT, mm Hg 42.581.6 41.981.9 NS
Baseline PVR, WU 9.880.5 10.880.9 NS
PVR during SHOT, WU 9.280.5 10.580.9 NS
Baseline pO2, mm Hg 66.782.0 60.582.8 NS
pO2 during SHOT, mm Hg 120.486.3 107.585.6 NS
Baseline SaO2, % 88.781.0 8581.3 <0.05
SaO2 during SHOT, % 96.180.7 96.680.5 NS
Baseline SvO2, % 58.381.1 52.281.9 <0.01
SvO2 during SHOT, % 65.180.9 63.182.2 NS
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 Fig. 1. Hemodynamic responses to supplemental oxygen. The 
100% values reflect baseline parameters (one circle for each pa-
rameter, CO, HR, PAP and PVR). The development of each of the 
four parameters during SHOT is given for the whole study popu-
lation (diamonds), PAH patients (triangles) and non-PAH pa-
tients (squares);  * * *  p  ! 0.001. 
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S a O 2  ! 88% (hazard ratio 4; range 1.2–13.6; p  ! 0.05) and 
S v O 2  ! 58% (hazard ratio 2.8; range 1.1–6.9; p  ! 0.05) were 
predictive of death. During SHOT, HR  1 72 beats/min 
(hazard ratio 4.3; range 1.4–12.8; p  ! 0.01) was the only 
prognostic hemodynamic parameter.
 During multivariate analysis of PH from chronic lung 
diseases or CTEPH, HR  1 72 beats/min during SHOT 
(hazard ratio 3.3; range 1.1–10.8; p  ! 0.05) remained an 
indicator of mortality.
 Survival Estimates Based on the Hemodynamic 
Response to Supplemental Oxygen  
 Ten of 45 patients with HR  ! 72 beats/min during 
SHOT (mean survival 58 months; 95% confidence inter-
val 49.37–65.53) and 22 of 59 patients with a higher HR 
died during the follow-up (mean survival time 42.3 
months; 95% confidence interval 33.5–51; p  ! 0.05; 
 fig. 2 ).
 Impact of Treatment on Survival 
 Since we did not perform a prospective therapeutic 
study with predefined treatment regimens, we are not 
able to evaluate different therapeutic effects. Twenty-
three patients (10 survivors) were on long-term oxygen 
therapy before study entry and an additional 3 patients 
were treated with oxygen after completion of the hemo-
dynamic study.
 Discussion 
 In this study, hemodynamic response patterns to 
SHOT were characterized across different etiologies of 
precapillary PH. In addition, we identified that a part of 
this response, namely a HR  ! 72 beats/min, was of prog-
nostic significance.
 In contrast to the pediatric PH patient population in 
whom vasoreactivity testing with oxygen during RHC is 
well established  [7–9] , this has never been investigated in 
a comparable cohort of adult PH patients. Therefore, the 
identification of any hemodynamic response pattern was 
of interest.
 In our current study, SHOT lowered HR, CO and pul-
monary artery pressure across all PH subgroups. In pa-
tients with PH from chronic lung disease or CTEPH, an 
additional small but significant reduction in PVR was de-
tectable during acute testing. Neither a reduction in HR 
nor PVR reduction was restricted to a certain level of hy-
poxemia. Of note, we observed these hemodynamic ef-
fects in a population with no proven effects of long-term 
oxygen therapy  [1] . In fact, patients were only mild hy-
poxemic (mean p O 2 64.5 mm Hg) at baseline.
 Our interpretation of this hemodynamic response is 
that supplementary oxygen decreased the sympathetic 
drive, leading to a reduction in HR, CO and, consequent-
ly, PAP. The potential of oxygen to decrease HR as a sign 
of less adrenergic drive may be of interest, since tachycar-
dia and a decreased HR variability have been interpreted 
as signs of RH insufficiency and autonomic dysfunction 
in PH and have been associated with a worse outcome 
 [11–13] . Naturally, it remains to be determined whether a 
reduction in HR induced by oxygen (or any other sub-
stance) could improve outcome in PH patients. However, 
a reduction in HR may be a therapeutic target in PH, par-
ticularly when considering the previously shown benefi-
cial effects of   -adrenoceptor antagonists in left heart 
failure inhibiting the   -adrenergic stimulus  [14] . How-
ever,   -blockers can have deleterious effects in PH pa-
tients  [15] . Recently, it has been shown that in patients 
Table 4.  Predictors of mortality in univariate analysis in the whole 
study population
Variable Hazard ratio p value
BNP >180 pg/ml 2.5 [1.2–5] <0.05
HR with O2 >72 b.p.m. 2.4 [1.1–5.2] <0.05
SaO2 <88% 2.1 [1–4.5] <0.05
SvO2 <58% 2.3 [1.1–4.6] <0.05
1.0
0.8
0.6
0.4
0.2
0
0 500 1,000 1,500 2,000 2,500
Su
rv
iv
al
Follow-up (days)
HR <72 beats/min
HR >72 beats/min
 Fig. 2. Effect of risk stratification by HR during SHOT (Kaplan-
Meier). 
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with left ventricular dysfunction HR reduction is a thera-
peutic target beyond the use of   -adrenergic blockade 
 [16] . Therefore, it is of interest that a reduction in HR can 
be achieved by SHOT in PH patients, presumably by an 
alleviation of the adrenergic stimulus.
 Even if the extent of PVR reduction was minor and of 
questionable clinical benefit, it was still statistically sig-
nificant and diverging between PH subgroups. In fact, 
PVR reduction was not seen in the PAH group, suggest-
ing a compensable alveolar hypoxia in CTEPH and PH 
from chronic lung disease. Combined with the effects on 
HR, the question of when oxygen should be administered 
in patients with CTEPH and PH from chronic lung dis-
ease may be raised. Currently, recommendations for 
long-term oxygen therapy in PH patients are based on 
studies in patients with chronic lung disease, including 
patients with and without PH  [1] .
 Typically, vasoreactivity testing is used in order to 
identify a subgroup of PAH patients with preserved pul-
monary vasodilatory reserve who show a favorable re-
sponse to calcium channel blocker therapy. In this set-
ting, the prognostic significance of hemodynamic re-
sponses has already been characterized for patients with 
idiopathic PAH. Classically, patients acutely respond 
with pulmonary vasodilation and either unchanged or 
increasing CO (depending on the agent). However, in our 
study, we tried to characterize a different hemodynamic 
pattern to SHOT besides pulmonary vasodilation, i.e. the 
reductions in CO and HR, but only minimal pulmonary 
vasodilation. Based on this, we would not call SHOT a 
true pulmonary vasoreactivity test at all. This might be 
in contrast to the pediatric population.
 The observation that part of this hemodynamic re-
sponse to oxygen has prognostic implications is of special 
interest. A reduction in HR during oxygen inhalation to 
 ! 72 beats/min turned out to be a predictor of survival in 
the whole study population, and during subgroup analy-
sis in patients with underlying chronic lung disease or 
CTEPH. Comparably, HR  1 70 beats/min was a negative 
prognostic parameter in patients with left ventricular 
dysfunction  [17] . In addition, tachycardia and reduced 
HR variability have been associated with a worse out-
come in PH patients  [11–13] . The potential to lower HR 
while breathing oxygen may be a sign of preserved auto-
nomic function. Peripheral oxygen shortage in PH main-
ly results from circulatory insufficiency, which is poten-
tially aggravated by gas exchange disturbances and
anemia, depending on the respective comorbidities. In 
order to overcome this shortage, compensatory circula-
tory mechanisms are activated. These include neurohu-
moral upregulation via   -adrenergic stimulation but also 
the activation of the natriuretic peptide system which is 
acutely  [18] and chronically  [19] regulated to counterreg-
ulate fluid retention in order to alleviate RH strain  [20–
23] . An overt clinical sign of such a situation is an in-
creased HR, which is in part thought to compensate 
threatening heart failure  [24–26] .
 Despite the observation that oxygen inhalation im-
proved a variety of hemodynamic parameters, HR  ! 72 
beats/min remained the only variable with prognostic 
implications in our cohort. Notably, HR without oxygen 
was not of prognostic significance. This underlines the 
merit of a test in order to disclose a subclinical oxygen 
deficit. Very recently, Minai et al.  [27]  have shown that a 
reduced HR recovery after moderate exercise (6-min 
walk test) is a predictor of clinical worsening in PAH pa-
tients. Our results are in line with these observations. 
However, in contrast to their study, we defined an abso-
lute cutoff value (72 beats/min) instead of a relative HR 
reduction.
 The preserved cardiac ability to actively regulate the 
mentioned compensatory mechanisms could be the ra-
tionale for the observation that a physiologic HR during 
oxygen inhalation was of prognostic significance in the 
group of patients with PH. In this context, the failure to 
increase HR in response to a submaximal exercise test 
was also of prognostic value  [28] . However, the prognos-
tic value of a preserved cardiac capability to respond to 
alleviated cardiac stress has not been investigated. Nev-
ertheless, during subgroup analysis, HR  ! 72 beats/min 
was no longer a predictor of mortality in the PAH group. 
One reason for this observation may be the pronounced 
chronic hypoxemic stress in PH compared to PAH pa-
tients and the higher compensatory HR at baseline. An-
other explanation is a better compensated PAH status de-
spite otherwise almost identical hemodynamic variables, 
leaving more space for improvement in the PH patients.
 Naturally, HR variability can be assessed noninvasive-
ly. However, this variability is different from what we in-
vestigated in this study and is typically not based upon a 
defined stimulus or withdrawal of a stimulus, respective-
ly. However, although this acute trial increases our patho-
physiological understanding, future assessments can be 
made without RHC.
 Our study clearly has limitations. First, we can only 
speculate on mechanisms that caused clinically question-
able significant improvements in hemodynamics during 
oxygen inhalation, especially the reduction in PVR. One 
potential explanation is the antagonizing effect of oxygen 
on hypoxic pulmonary vasoconstriction  [29] , which is at 
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least in part mediated via the oxygen-dependent produc-
tion of endogenous nitric oxide, a potent pulmonary
vasodilator. Moreover, experimental and clinical data 
suggest an impairment in the catabolism of asymmetric 
dimethylarginine in chronic hypoxia-induced PH  [30] . 
This may be of importance since asymmetric dimethyl-
arginine is an endogenous inhibitor of nitric oxide syn-
thesis and related to the severity of PH  [31] . The fact that 
in PAH patients a PVR reduction was not observed is in 
line with this observation, since usually these patients do 
not have alveolar hypoxia. Nevertheless, even PAH pa-
tients responded to SHOT with reductions in HR, CO 
and PAP.
 Although BNP is a well-established parameter of neu-
rohumoral activation, it may not be sufficient to rely on 
one marker alone to describe neurohumoral activation. 
However, adrenergic activation is mainly regulated in a 
paracrine fashion and we might have missed such path-
ways by measuring catecholamine levels anyway. We did 
not perform a dose-response curve for supplemental oxy-
gen. Applying 5 l/min of oxygen was a pragmatic ap-
proach in order to standardize dosing. Therefore, a con-
clusion cannot be drawn regarding the threshold of oxy-
gen tension and/or arterial oxygen saturation that would 
cause a significant reduction in the oxygen deficit. How-
ever, the value of the additional information of such a 
dose-response curve is questionable. Instead, we per-
formed a stepwise statistical analysis in order to identify 
a threshold for hypoxemia. As a matter of fact, our study 
population was too small to allow further subgroup anal-
ysis, especially in terms of further subdivision of the non-
PAH PH group. Finally, we cannot conclude on the long-
term effects of chronic oxygen therapy, since we only 
characterized the acute response to supplemental oxygen.
 Despite these limitations, we were able to demonstrate 
that SHOT provokes a characteristic hemodynamic re-
sponse with a reduction in HR, CO and, consequently, 
PAP in patients with different forms of precapillary PH. 
In addition, we evidenced that the ability to reduce HR 
 ! 72 beats/min in response to SHOT may confer a sur-
vival benefit in PH.
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